FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2810154626> ?p ?o ?g. }

• W2810154626 abstract "Triple negative breast cancers (TNBCs) represent 15-20% of all breast cancers and are often associated with a poor prognosis. The lack of targeted therapies for TNBCs contributes to higher mortality rates. Therefore, there is a need to identify survival pathways that may be targeted in TNBCs. Aberrations in the Phosphoinositide-3-kinase (PI3K) and Mitogen Activated Protein Kinase (MAPK) pathways have been linked to increased breast cancer proliferation and survival. It has been proposed that these survival characteristics are enhanced through compensatory signaling and crosstalk mechanisms. The crosstalk between PI3K/Akt and MEK1/2/ERK1/2 has been characterized in several systems. However, new evidence suggests that MEK5/ERK5, a member of the MAPK family, is a key component in the proliferation and survival of several aggressive cancers. In this study, we examined the effects of dual inhibition of PI3K/Akt and MEK5/ERK5 in three TNBC cell lines: MDA-MB-231, BT549, and MDA-MB-468. We achieved Akt inhibition by using the clinically relevant inhibitors MK-2206 and Ipatasertib. We used a novel compound synthesized in our lab, SC-1-181, and the research tool, XMD8-92, to inhibit MEK5 and ERK5, respectively. Our results indicate that the dual inhibition strategy was more effective than single inhibition due to the loss of crosstalk between the two pathways. In particular, a loss of Bad phosphorylation at two distinct sites was observed with dual inhibition. Interestingly, this signaling pattern was observed without disturbing the ERK1/2 pathway. Furthermore, the inhibition of both pathways led to p21 restoration, decreased cell proliferation, and induced apoptosis. Additionally, the dual inhibition strategy was determined to be synergistic in TNBCs and was nontoxic in non-neoplastic cell lines. Lastly, we evaluated the contributions of Bromodomain 4 (BDR4), an off-target effect of XMD8-92, to the synergy mechanism. In summary, the results from this study provide a unique prospective into the utility of a novel dual inhibition strategy for targeting TNBCs. Citation Format: Thomas D. Wright, Christopher Raybuck, Nathan Gartland, Katy Wendekier, Darlene Monlish, Suravi Chakrabarty, Patrick T. Flaherty, Matthew E. Burow, Jane E. Cavanaugh. Evaluation of synergistic PI3K/Akt and MEK5/ERK5 inhibition in triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2392." @default.
• W2810154626 created "2018-07-10" @default.
• W2810154626 creator A5020539295 @default.
• W2810154626 creator A5026020049 @default.
• W2810154626 creator A5030511518 @default.
• W2810154626 creator A5048983251 @default.
• W2810154626 creator A5056185739 @default.
• W2810154626 creator A5057334251 @default.
• W2810154626 creator A5067088371 @default.
• W2810154626 creator A5076152468 @default.
• W2810154626 creator A5085047557 @default.
• W2810154626 date "2018-07-01" @default.
• W2810154626 modified "2023-10-14" @default.
• W2810154626 title "Abstract 2392: Evaluation of synergistic PI3K/Akt and MEK5/ERK5 inhibition in triple-negative breast cancer" @default.
• W2810154626 doi "https://doi.org/10.1158/1538-7445.am2018-2392" @default.
• W2810154626 hasPublicationYear "2018" @default.
• W2810154626 type Work @default.
• W2810154626 sameAs 2810154626 @default.
• W2810154626 citedByCount "0" @default.
• W2810154626 crossrefType "proceedings-article" @default.
• W2810154626 hasAuthorship W2810154626A5020539295 @default.
• W2810154626 hasAuthorship W2810154626A5026020049 @default.
• W2810154626 hasAuthorship W2810154626A5030511518 @default.
• W2810154626 hasAuthorship W2810154626A5048983251 @default.
• W2810154626 hasAuthorship W2810154626A5056185739 @default.
• W2810154626 hasAuthorship W2810154626A5057334251 @default.
• W2810154626 hasAuthorship W2810154626A5067088371 @default.
• W2810154626 hasAuthorship W2810154626A5076152468 @default.
• W2810154626 hasAuthorship W2810154626A5085047557 @default.
• W2810154626 hasConcept C11960822 @default.
• W2810154626 hasConcept C120665830 @default.
• W2810154626 hasConcept C121332964 @default.
• W2810154626 hasConcept C121608353 @default.
• W2810154626 hasConcept C126322002 @default.
• W2810154626 hasConcept C169822122 @default.
• W2810154626 hasConcept C184235292 @default.
• W2810154626 hasConcept C2780110267 @default.
• W2810154626 hasConcept C502942594 @default.
• W2810154626 hasConcept C530470458 @default.
• W2810154626 hasConcept C57074206 @default.
• W2810154626 hasConcept C62478195 @default.
• W2810154626 hasConcept C71924100 @default.
• W2810154626 hasConcept C75217442 @default.
• W2810154626 hasConcept C86554907 @default.
• W2810154626 hasConcept C86803240 @default.
• W2810154626 hasConcept C95444343 @default.
• W2810154626 hasConceptScore W2810154626C11960822 @default.
• W2810154626 hasConceptScore W2810154626C120665830 @default.
• W2810154626 hasConceptScore W2810154626C121332964 @default.
• W2810154626 hasConceptScore W2810154626C121608353 @default.
• W2810154626 hasConceptScore W2810154626C126322002 @default.
• W2810154626 hasConceptScore W2810154626C169822122 @default.
• W2810154626 hasConceptScore W2810154626C184235292 @default.
• W2810154626 hasConceptScore W2810154626C2780110267 @default.
• W2810154626 hasConceptScore W2810154626C502942594 @default.
• W2810154626 hasConceptScore W2810154626C530470458 @default.
• W2810154626 hasConceptScore W2810154626C57074206 @default.
• W2810154626 hasConceptScore W2810154626C62478195 @default.
• W2810154626 hasConceptScore W2810154626C71924100 @default.
• W2810154626 hasConceptScore W2810154626C75217442 @default.
• W2810154626 hasConceptScore W2810154626C86554907 @default.
• W2810154626 hasConceptScore W2810154626C86803240 @default.
• W2810154626 hasConceptScore W2810154626C95444343 @default.
• W2810154626 hasLocation W28101546261 @default.
• W2810154626 hasOpenAccess W2810154626 @default.
• W2810154626 hasPrimaryLocation W28101546261 @default.
• W2810154626 hasRelatedWork W1993118022 @default.
• W2810154626 hasRelatedWork W2006105451 @default.
• W2810154626 hasRelatedWork W2012503947 @default.
• W2810154626 hasRelatedWork W2055946353 @default.
• W2810154626 hasRelatedWork W2107409165 @default.
• W2810154626 hasRelatedWork W2410428173 @default.
• W2810154626 hasRelatedWork W2548979602 @default.
• W2810154626 hasRelatedWork W2809291655 @default.
• W2810154626 hasRelatedWork W2810154626 @default.
• W2810154626 hasRelatedWork W3127435265 @default.
• W2810154626 isParatext "false" @default.
• W2810154626 isRetracted "false" @default.
• W2810154626 magId "2810154626" @default.
• W2810154626 workType "article" @default.